Endomyocardial Biopsy Market Size Worth $ 599.52 Million By 2032 | CAGR: 6.6%

Endomyocardial Biopsy Market Size Worth $ 599.52 Million By 2032 | CAGR: 6.6%

The global endomyocardial biopsy market size is expected to reach USD 599.52 million by 2032, according to a new study by Polaris Market Research. The report “Endomyocardial Biopsy Market Share, Size, Trends, Industry Analysis Report, By Product (Forceps, Accessories); By Tip (Straight, Maxi-curved, Pre-curved); By End-use (Hospitals, Ambulatory Surgical Centers); By Region, And Segment Forecasts, 2023 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

With the increasing number of heart transplants, there is also a rising need for monitoring and detection of possible rejection. Endomyocardial biopsy procedures play a crucial role in diagnosing heart rejection and are often performed in the post-transplant period. Therefore, the increasing number of heart transplants would indirectly lead to the growth of the market.

Increasing prevalence of cardiovascular disorders, such as coronary artery disease, heart failure, and arrhythmias, is a major driving factor for the growth of the market. The rising demand for the minimally invasive surgeries, which offer benefits such as reduced pain, faster recovery, & shorter hospital stays, has also contributed to the growth of the market. In addition, favorable reimbursement policies for coronary intervention procedures have encouraged healthcare providers to perform endomyocardial biopsies as a diagnostic tool for evaluating the graft function and detecting rejection in heart transplant patients.

Emerging economies present a huge opportunity for growth and expansion of the endomyocardial biopsy market. The increasing healthcare spending and investments in the healthcare infrastructure in these economies are expected to drive the demand for endomyocardial biopsy procedures. Multinational companies are increasingly investing in these regions to introduce their products and capture a significant portion of the market. This trend is expected to continue during the forecast period, driving the growth of the endomyocardial biopsy market in the emerging economies.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/endomyocardial-biopsy-market/request-for-sample

Market growth is further supported by various regulatory agencies such as the U.S. FDA, Health Canada, EMA, COFEPRIS, MHRA, & CDSCO, which have taken initiatives to support the research and development in this field. For example, in March 2020, the U.S. FDA granted Fast Track designation to IVERIC Bio’s Zimura for the treatment of patients with geographic atrophy (GA) secondary to AMD. It is a pegylated RNA aptamer, which is synthesized & administered by the intra-vitreal injection. It works by the inhibition of factor C5, considered responsible for onset of AMD.

Endomyocardial Biopsy Market Report Highlights

  • Forceps segment dominated the market, owing to the development of innovative forceps with better grip and features
  • Straight tip segment accounted for the larger market share. This is due to the fact straight tips causes less damage to the tissues during biopsy procedures
  • Hospitals segment garnered the largest share. Hospitals are better equipped equipment and have dedicated doctors and nurses
  • Asia Pacific is projected to register a higher growth rate, owing to the presence of large patient pool, huge untapped population, and favorable government policies for research.
  • The global players include Argon Medical, Cordis, Mermaid Medical, Terumo Corp., Scholten Surgicals, Changzhou Lookmed, and Fehling Instruments.

Polaris Market Research has segmented the endomyocardial biopsy market report based on product, tip, end use, and region:

Endomyocardial Biopsy, Product Outlook (Revenue - USD Million, 2019 - 2032)

  • Forceps
  • Accessories

Endomyocardial Biopsy, Tip Outlook (Revenue - USD Million, 2019 - 2032)

  • Maxi-curved
  • Straight
  • Pre-curved
  • Others

Endomyocardial Biopsy, End Use Outlook (Revenue - USD Million, 2019 - 2032)

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

Endomyocardial Biopsy, Regional Outlook (Revenue - USD Million, 2019 - 2032)

  • North America
    • U.S.
    • Canada
    • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
    • Netherlands
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Indonesia
    • Malaysia
  • Latin America
    • Argentina
    • Brazil
    • Mexico
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • Israel
    • South Africa

Endomyocardial Biopsy Market Report Scope

Report Attributes


Market size value in 2023

USD 338.13 million

Revenue forecast in 2032

USD 599.52 million


6.6% from 2023 – 2032

Base year


Historical data

2019 – 2021

Forecast period

2023 – 2032

Quantitative units

Revenue in USD million and CAGR from 2023 to 2032

Segments covered

By Product, By Tip, By End Use, By Region

Regional scope

North America, Europe, Asia Pacific, Latin America; Middle East & Africa

Key companies

Argon Medical, Cordis, Mermaid Medical, Terumo Corp., Scholten Surgicals, Changzhou Lookmed, and Fehling Instruments.

For Specific Research Requirements

Request for Customized Report